solengepras

AssetAlso CVN-424, solangepras

GPR6 inverse agonist that modulates striatal motor pathways to reduce Parkinson’s motor fluctuations.

Stage
Phase 3
Modality
Small molecule
Target
GPR6
1
Indication
0
Trials
1
Developer

Indications

1

In the full profile

  • Targets and what it contains1
  • Owner and partners1
  • Competitors12

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets